LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer Meeting Abstract
| Authors: | Saura, C.; de Azambuja, E.; Dubsky, P.; Oliveira, M.; Saini, K. S.; Fes, C.; Lin, R. S.; Wilson, T. R.; Fredickson, J.; Parmar, H.; Hsu, J. Y.; Piccard, M.; Gnant, M.; Baselga, J. |
| Abstract Title: | LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer |
| Meeting Title: | 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 75 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2014 Dec 9-13 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-05-01 |
| Language: | English |
| ACCESSION: | WOS:000356730200076 |
| DOI: | 10.1158/1538-7445.sabcs14-ot1-1-01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-1-01 -- 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium -- DEC 09-13, 2014 -- San Antonio, TX -- S -- Source: Wos |
